Table 2.
Dose-dependent reduction of clinical parameters by liposomal dexamethasone phosphate on Days 19 and 28 in adjuvant arthritis
| Experiment 4 | Arthritis score | Paw volume | |||
|---|---|---|---|---|---|
| Treatment | Day 19 | Day 28 | Day 19 | Day 28 | |
| AA/PBS | -- | -- | -- | -- | |
| AA/DxM-P | 0.01 mg/kg | -10% ± 9.3% | + 6% ± 11.9% | -18% ± 12.9% | -12% ± 8.4% |
| AA/DxM-P | 0.1 mg/kg | -25% ± 6.9% | -4% ± 10.3% | -34% ± 10.1% | + 9% ± 27.0% |
| AA/DxM-P | 1.0 mg/kg | -69% ± 12.5% + | -27% ± 16.4% | -71% ± 10.4% + | -23% ± 16.0% |
| AA/liposomal DxM-P | 0.01 mg/kg | -20% ± 14.0% | -13% ± 18.5% | -21% ± 21.1% | -5% ± 26.7% |
| AA/liposomal DxM-P | 0.1 mg/kg | -38% ± 23.7% | -28% ± 16.9% | -44% ± 15.4% | -36% ± 12.2% |
| AA/liposomal DxM-P | 1.0 mg/kg | -96% ± 2.0% ++ $$ § * | -59% ± 20.0% | -86% ± 5.1% ++ $$ §§ | -58% ± 18.0% |
Reduction of arthritis score and paw volume on Day 19 (maximal efficacy of therapy) and Day 28 of AA after treatment with free DxM-P (3 × 1 mg/kg, 3 × 0.1 mg/kg, or 3 × 0.01 mg/kg) or liposomal DxM-P (3 × 1 mg/kg, 3 × 0.1 mg/kg, or 3 × 0.01 mg/kg) compared to AA/PBS (Experiment 4 corresponds to the data in Figure 2).
Data are expressed as means ± standard error of the mean.
+ P ≤ 0.05, ++ P ≤ 0.01 vs. AA/PBS; $$ P ≤ 0.01 vs. AA/liposomal DxM-P 0.01 mg/kg; § P ≤ 0.05, §§ P ≤ 0.01 vs. AA/liposomal DxM-P 0.1 mg/kg; * P ≤ 0.05 vs. AA/DxM-P 1 mg/kg.